Compare GRFS & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | CHE |
|---|---|---|
| Founded | 1940 | 1970 |
| Country | Spain | United States |
| Employees | 25247 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.6B |
| IPO Year | N/A | 1994 |
| Metric | GRFS | CHE |
|---|---|---|
| Price | $7.62 | $371.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $10.15 | ★ $498.00 |
| AVG Volume (30 Days) | ★ 818.8K | 280.3K |
| Earning Date | 07-28-2022 | 04-22-2026 |
| Dividend Yield | ★ 1.85% | 0.64% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 18.34 |
| Revenue | N/A | ★ $2,529,978,000.00 |
| Revenue This Year | $5.33 | $6.60 |
| Revenue Next Year | $6.50 | $6.15 |
| P/E Ratio | ★ $18.67 | $20.38 |
| Revenue Growth | N/A | ★ 4.06 |
| 52 Week Low | $6.19 | $368.44 |
| 52 Week High | $11.14 | $623.61 |
| Indicator | GRFS | CHE |
|---|---|---|
| Relative Strength Index (RSI) | 32.80 | 27.11 |
| Support Level | N/A | N/A |
| Resistance Level | $9.11 | $458.07 |
| Average True Range (ATR) | 0.21 | 8.93 |
| MACD | -0.03 | -1.70 |
| Stochastic Oscillator | 17.39 | 12.34 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.